SARS-CoV-2 S1 oqsilini Saccharomyces cerevisiae hujayralarida rekombinant ekspressiya qilishni baholash

Evaluation of the recombinant expression of the SARS-CoV-2 S1 protein in Saccharomyces cerevisiae cells

Article Sidebar

PDF (Uzbek)
Published: 2026-10-30
DOI: https://doi.org/10.66073/ReFocus-Conf/3010040
Keywords:
S1 protein, SARS-CoV-2, S. cerevisiae, recombinant expression, SDS-PAGE, Western blot

Main Article Content

Toshboyeva Fotima Nuriddin kizi
National University of Uzbekistan named after Mirzo Ulugbek
Ayubov M.S.
Center of Genomics and Bioinformatics of the Academy of Sciences of the Republic of Uzbekistan
Ravshanov Hamrokul Toymurod ugli
National University of Uzbekistan named after Mirzo Ulugbek

Abstract

This study analyzed a technological approach aimed at evaluating the recombinant expression of the SARS-CoV-2 S1 protein in Saccharomyces cerevisiae cells. The study considered an S. cerevisiae culture and an expression system based on the pYES2-S1-Zeo construct. SDS-PAGE and Western blot methods were intended for the detection of the recombinant protein. The molecular mass of the S1 protein, 61 kDa, was indicated as the main criterion for electrophoretic identification. The study focused on evaluating a recombinant antigen production platform, while the determination of final vaccine efficacy is to be carried out at a subsequent stage.

Article Details

Issue

Vol. 1 No. 8 (2026): Status and Development Prospects of Fundamental and Applied Microbiology: The Viewpoint of Young Scientists

Section

Biotechnology, Molecular Biology and Bioinformatics
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Toshboyeva Fotima Nuriddin kizi, Ayubov M.S., & Ravshanov Hamrokul Toymurod ugli. (2026). Evaluation of the recombinant expression of the SARS-CoV-2 S1 protein in Saccharomyces cerevisiae cells. Partner Conferences of the International Scientific Journal Research Focus, 1(8), 160-163. https://doi.org/10.66073/ReFocus-Conf/3010040

References

Ayubov, M. S.; Buriev, Z. T.; Mirzakhmedov, M. K.; Yusupov, A. N.; Usmanov, D. E.; Shermatov, S. E.; Ubaydullaeva, K. A.; Abdurakhmonov, I. Y., Profiling of the most reliable mutations from sequenced SARS-CoV-2 genomes scattered in Uzbekistan. PLoS One 2022, 17 (3), e0266417. DOI: https://doi.org/10.1371/journal.pone.0266417

Ayubov MS, Mirzakhmedov MK, Yusupov AN, Asrorov AM, Nosirov BV, Usmanov DE, Shermatov SE, Ubaydullaeva KA, Abdukarimov A, Buriev ZT, Abdurakhmonov IY. Most accurate mutations in SARS-CoV-2 genomes identified in Uzbek patients show novel amino acid changes. Front Med (Lausanne). 2024 May 31;11:1401655. doi: 10.3389/fmed.2024.1401655. DOI: https://doi.org/10.3389/fmed.2024.1401655

Pardi N, Krammer F. mRNA vaccines for infectious diseases—advances, challenges and opportunities. Nat Rev Drug Discov. 2024;23(11):838-61. doi:10.1038/s41573-024-01042-y. DOI: https://doi.org/10.1038/s41573-024-01042-y

Tan BEK, Tham SK, Poh CL. mRNA vaccine development in the fight against zoonotic viral diseases. Viruses. 2025;17(7):960. doi:10.3390/v17070960. DOI: https://doi.org/10.3390/v17070960